丙戊酸钠对戊四氮致痫大鼠海马组织粘着斑激酶表达的影响

目的:探讨抗癫痫药丙戊酸钠（VPA）对戊四氮（PTZ）致痫模型大鼠海马组织中粘着斑激酶（FAK）、FAK-pY397表达水平的影响。方法:将75只大鼠随机分为正常对照组,模型组,VPA低、中、高剂量组(150,300,600 mg·kg-1·d-1) 5组,每组15只。造模大鼠连续腹腔注射戊四氮32 mg·kg-1·d-14周,密切观察大鼠行为学变化。造模成功后,VPA各组给予相应剂量VPA灌胃,连续2周。苏木精-伊红（HE）染色观察大鼠海马组织变化;免疫组化及酶联免疫吸附法（ELISA）检测大鼠外周血清及海马组织中FAK、FAK-pY397及整合素表达情况。结果:与模型组比较,VPA各组癫痫症状有明显缓解,细胞凋亡情况有所改善;免疫组化发现VPA组FAK-pY397的表达明显下降,且随着VPA剂量的加大,FAK-pY397的表达有下降趋势,ITGα3表达组间无显著差异; VPA低、中、高剂量组海马组织中FAK,FAK-pY397及整合素ITGβ1表达水平下降,差异具有显著性（P <0. 05）;外周血清中FAK及整合素ITGβ1蛋白表达水平显著下降（P <0. 05）,但FAK-pY397表达无明显变化。结论:VPA可能通过抑制癫痫大鼠海马组织中FAK-pY397及ITGβ1的表达,参与或影响癫痫过程。漳州市自然科学基金课题(编号:ZZ2017J41

The Influence of Personality on Employment Quality： Moderating Effect of Psychological Capital

为了探索人格和心理资本对就业质量的影响,研究采用问卷调查的方法,对303名职校毕业生进行调查。结果发现:①大五人格5个维度均显著影响心理资本;②大五人格的外向性会在一定程度上影响收入水平,但心理资本会完全中介人格对收入的预测作用。大五人格的宜人性、尽责性能显著影响工作满意度,但心理资本也会完全中介人格对工作满意度的预测作用。表明心理资本是影响就业质量的重要因素,学校录用学生、企业招聘员工可适当的考察其心理资本状况

酪氨酸羟化酶缺乏症导致多巴反应性肌张力不全患儿临床及遗传特点

目的探讨酪氨酸羟化酶缺乏症（THD）导致多巴反应性肌张力不全患儿的临床、遗传特点、治疗和预后。方法回顾分析2017年6月至2020年11月神经内科住院部收治的6例THD导致多巴反应性肌张力不全患儿的临床资料及基因检测结果。结果6例患儿来自4个不同家庭，男4例，女2例，均患有肌张力障碍。中位发病年龄为11.5个月（3个月～4岁），6例患者发现TH基因复合杂合突变。TH基因共检测到7个突变，包括5个已知突变c.698G&gt;A（p.R233H）、c.1145T&gt;C（p.I382T）、c.739G&gt;A（p.G247S）、c.1481C&gt;T（p.T494M）、c.880G&gt;C（p.G294R），以及2个新突变： c.1279A＞G（p.Y427H）和 c.1128_1138del（p.Q377GfsTer12）。他们服用美多芭治疗，维持剂量为2～15 mg/（kg·d）。所有患者对美多芭反应良好，但病例4遗留有脊柱侧弯。结论THD临床表现多样，尽早识别和启动左旋多巴治疗，可明显改善预后。本研究检测到TH基因2个新的突变，错义突变c.1279A&gt;G及移码突变c.1128_1138del。本研究拓宽了THD的基因型谱，为了解THD的分子机制提供了新思路。基因检测是THD最重要的诊断方法，对后续治疗及遗传咨询有指导意义

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^